Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 12, 2015 (12 years ago)

Levodopa 250 mg NSR Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Levodopa 250 mg NSR Capsules,Health Innov Pharmacy, 295 Pinehurst Ave, Southern Pines, NC 28387, (910) 246-5155

Drug: Levodopa

Recalling firm
Health Innovations Pharmacy, Inc
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1036-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levodopa recalls

See all
Class II · Moderate risk

Carbidopa

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Ongoing Labeling / mix-up Rising Pharma Holding, Inc. NDC 16571-691-01 D-0029-2026
Class II · Moderate risk

Carbidopa and Levodopa Tablets

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Terminated Packaging defect The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class II · Moderate risk

Duopa (carbidopa and levodopa enteral suspension)

Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life

Terminated Stability / shelf life AbbVie Inc. NDC 0074-3012-07 D-0495-2017

Other recalls by Health Innovations Pharmacy, Inc

All 2015 recalls
Class II · Moderate risk

Phen 15 mg - Topri 92 mg SR Cap

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Terminated Sterility / contamination Health Innovations Pharmacy, Inc D1051-2015
Class II · Moderate risk

Hydrocortisone 1.6 mg/0.5 mL Susp

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Terminated Sterility / contamination Health Innovations Pharmacy, Inc D-1062-2015
Class II · Moderate risk

Nystatin 50

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Terminated Sterility / contamination Health Innovations Pharmacy, Inc D-1061-2015
Class II · Moderate risk

Coconut Oil Suppository

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Terminated Sterility / contamination Health Innovations Pharmacy, Inc D-1060-2015